Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both

We read with great interest the recently reported work regarding clinical profiles for metabolic dysfunction-associated steatotic liver disease (MASLD) and non-alcoholic fatty liver disease (NAFLD) by Younossi [1] Younossi Z.M. Paik J.M. Stepanova M. et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024; Abstract Full Text Full Text PDF Scopus (2) Google Scholar . Metabolic dysfunction-associated fatty liver disease (MAFLD) and MASLD were introduced as new terminologies to address the limitations associated with NAFLD [2] Rinella M.E. Lazarus J.V. Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79: 1542-1556 Abstract Full Text Full Text PDF PubMed Scopus (323) Google Scholar ,[3] Eslam M. Newsome P.N. Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73: 202-209 Abstract Full Text Full Text PDF PubMed Scopus (2195) Google Scholar . MASLD encompasses patients with at least one of five cardiometabolic risk factors and captures more lean patients than MAFLD. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver diseaseJournal of HepatologyPreviewRecently, the term metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). Concern remains regarding whether the evidence generated under the NAFLD definition can be used for MASLD. We compared the clinical profile and outcomes of NAFLD to MASLD using tertiary care- and population-based data. Full-Text PDF